This site is intended for healthcare professionals
Drug news

Results of ACCURATE study show advantage of Axium Neurostimulator System in pain relief- St Jude Medical

Read time: 1 mins
Last updated:13th Dec 2015
Published:13th Dec 2015
Source: Pharmawand

St. Jude Medical has announced long term data from the ACCURATE study has confirmed dorsal root ganglion (DRG) stimulation with the St. Jude Medical Axium Neurostimulator System provides sustained and superior pain relief over traditional spinal cord stimulation (SCS) in patients with complex regional pain syndrome (CRPS) or peripheral causalgia. In addition, patients receiving DRG stimulation reported better therapeutic targeting and a reduction in paresthesia (the tingling feeling common to traditional SCS) compared to traditional tonic SCS.

Results show sustained and superior pain relief: after 12 months, the ACCURATE study demonstrated a statistically significantly number of patients receiving DRG stimulation achieved meaningful pain relief and greater treatment success when compared to patients receiving traditional SCS (74.2 percent vs. 53 percent). The study also shows improved therapeutic targeting: Nearly all patients receiving DRG stimulation reported better stimulation targeting in their area of pain without extraneous paresthesia than patients receiving traditional SCS (94.5 percent vs. 61.2 percent). Finally it shows reduced paresthesia: After 12 months, more than a third of patients who received DRG stimulation were experiencing greater than 80 percent pain relief with no paresthesia. St. Jude Medical submitted their premarket approval submission to the FDA for approval of DRG stimulation in Q1 2015.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.